News and Announcements
CEO Dr James Garner speaks about GDC-0084 data with Proactive Investors
- Published November 25, 2019 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Our CEO, Dr James Garner discussed the significance of the interim efficacy data from Kazia’s phase II trial of GDC-0084 in glioblastoma in an interview with Proactive Investors.
In the interview, Dr Garner talks about:
- How the median progression-free survival rate of 8.3 months strongly suggests that GDC-0084 is delaying the progression of glioblastoma in the patients treated
- How the data signals that GDC-0084 may be extending life expectancy for the patients treated
- How the data compares to the existing treatment option for glioblastoma, temozolomide
- The next steps for the phase II study and Kazia more generally
Watch the video interview here
About KaziaTherapeutics Limited
Kazia Therapeutics Limited (ASX: KZA, NASDAQ: KZIA) is an innovative oncology-focused biotechnology company, based in Sydney, Australia. Our pipeline includes two clinical-stage drug development candidates, and we are working to develop therapies across a range of oncology indications.
Company Updates
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Backed By Leading Investment Groups and Family Offices
